WO2006089843A3 - Forme medicamenteuse orale microparticulaire anti-mesusage - Google Patents

Forme medicamenteuse orale microparticulaire anti-mesusage Download PDF

Info

Publication number
WO2006089843A3
WO2006089843A3 PCT/EP2006/050784 EP2006050784W WO2006089843A3 WO 2006089843 A3 WO2006089843 A3 WO 2006089843A3 EP 2006050784 W EP2006050784 W EP 2006050784W WO 2006089843 A3 WO2006089843 A3 WO 2006089843A3
Authority
WO
WIPO (PCT)
Prior art keywords
misuse
active ingredient
prevent
oral
drug form
Prior art date
Application number
PCT/EP2006/050784
Other languages
English (en)
Other versions
WO2006089843A2 (fr
Inventor
Florence Guimberteau
Remi Meyrueix
Gerard Soula
Original Assignee
Flamel Tech Sa
Florence Guimberteau
Remi Meyrueix
Gerard Soula
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flamel Tech Sa, Florence Guimberteau, Remi Meyrueix, Gerard Soula filed Critical Flamel Tech Sa
Priority to EP06708128A priority Critical patent/EP1845958A2/fr
Priority to CA002596965A priority patent/CA2596965A1/fr
Priority to US11/883,935 priority patent/US20090041838A1/en
Priority to JP2007553626A priority patent/JP2008529990A/ja
Publication of WO2006089843A2 publication Critical patent/WO2006089843A2/fr
Publication of WO2006089843A3 publication Critical patent/WO2006089843A3/fr
Priority to US12/560,044 priority patent/US20100266701A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Abstract

Le domaine de la présente invention est celui des formes pharmaceutiques orales microparticulaires solides dont la composition permet d'éviter le mésusage du principe actif pharmaceutique (PA) qu'elles contiennent. Le but visé par la présente invention est de prévenir le détournement des médicaments solides oraux, pour tout autre usage que l'usage ou les usages thérapeutiques officiellement approuvés par les autorités de santé publique compétentes. Le but est également de fournir de nouveaux médicaments analgésiques permettant à la fois la prévention du mésusage et de l'addiction à certains analgésiques et/ou le contrôle de la variabilité de la concentration plasmatique et/ou la facilitation de l'administration orale ; et/ou l'association de analgésiques entre eux et/ou avec un ou plusieurs principes actifs dans une même forme orale. L'invention concerne une forme médicamenteuse orale et solide, comprenant des moyens anti-mésusage et au moins un principe actif (PA), caractérisée en ce que au moins une partie du PA est contenue dans des microparticules et caractérisée en ce que les moyens anti-mésusage comprennent des moyens (a) anti broyage prévus pour permettre aux microparticules de PA de résister au broyage, de manière à éviter le mésusage. La forme médicamenteuse selon l'invention peut comprendre en outre des moyens (b) prévus pour éviter le mésusage du PA après une éventuelle extraction liquide.
PCT/EP2006/050784 2005-02-08 2006-02-08 Forme medicamenteuse orale microparticulaire anti-mesusage WO2006089843A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP06708128A EP1845958A2 (fr) 2005-02-08 2006-02-08 Forme medicamenteuse orale microparticulaire anti-mesusage
CA002596965A CA2596965A1 (fr) 2005-02-08 2006-02-08 Forme medicamenteuse orale microparticulaire anti-mesusage
US11/883,935 US20090041838A1 (en) 2005-02-08 2006-02-08 Anti-Misuse Microparticulate Oral Drug Form
JP2007553626A JP2008529990A (ja) 2005-02-08 2006-02-08 誤用防止用の微小粒子状経口薬物形態
US12/560,044 US20100266701A1 (en) 2005-02-08 2009-09-15 Anti-misuse microparticulate oral drug form

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0550364A FR2881652B1 (fr) 2005-02-08 2005-02-08 Forme pharmaceutique orale microparticulaire anti-mesuage
FR0550364 2005-02-08

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US11/648,605 Continuation US20070264326A1 (en) 2005-02-08 2007-01-03 Anti-misuse oral microparticle medicinal formulation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/560,044 Continuation US20100266701A1 (en) 2005-02-08 2009-09-15 Anti-misuse microparticulate oral drug form

Publications (2)

Publication Number Publication Date
WO2006089843A2 WO2006089843A2 (fr) 2006-08-31
WO2006089843A3 true WO2006089843A3 (fr) 2007-03-22

Family

ID=35058447

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/050784 WO2006089843A2 (fr) 2005-02-08 2006-02-08 Forme medicamenteuse orale microparticulaire anti-mesusage

Country Status (7)

Country Link
US (2) US20090041838A1 (fr)
EP (1) EP1845958A2 (fr)
JP (1) JP2008529990A (fr)
CN (1) CN101151022A (fr)
CA (1) CA2596965A1 (fr)
FR (1) FR2881652B1 (fr)
WO (1) WO2006089843A2 (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040234602A1 (en) 2001-09-21 2004-11-25 Gina Fischer Polymer release system
US20040253310A1 (en) 2001-09-21 2004-12-16 Gina Fischer Morphine polymer release system
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
FR2830447B1 (fr) * 2001-10-09 2004-04-16 Flamel Tech Sa Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
IL164222A0 (en) 2002-04-09 2005-12-18 Flamel Tech Sa Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s)
ATE495732T1 (de) 2003-03-26 2011-02-15 Egalet As Morphin-system mit kontrollierter freisetzung
WO2006133733A1 (fr) 2005-06-13 2006-12-21 Flamel Technologies Forme posologique orale comportant un systeme anti-abus
FR2892937B1 (fr) * 2005-11-10 2013-04-05 Flamel Tech Sa Forme pharmaceutique orale microparticulaire anti-mesusage
US8652529B2 (en) 2005-11-10 2014-02-18 Flamel Technologies Anti-misuse microparticulate oral pharmaceutical form
US20080069891A1 (en) * 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
EP2155167A2 (fr) 2007-06-04 2010-02-24 Egalet A/S Compositions pharmaceutiques à libération contrôlée pour un effet prolongé
AU2008338207A1 (en) 2007-12-17 2009-06-25 Labopharm (Barbados) Limited Misuse preventative, controlled release formulation
FR2936709B1 (fr) * 2008-10-02 2012-05-11 Ethypharm Sa Comprimes alcoolo-resistants.
ES2509497T3 (es) 2008-12-16 2014-10-17 Paladin Labs Inc. Formulación de liberación controlada para evitar un uso indebido
NZ594207A (en) 2009-02-06 2013-03-28 Egalet Ltd Immediate release composition resistant to abuse by intake of alcohol
WO2010100414A1 (fr) 2009-03-04 2010-09-10 Orexo Ab Formulation permettant d'empêcher une consommation abusive
EA027618B1 (ru) 2009-05-08 2017-08-31 Эмпликюре Аб Композиция для непрерывной доставки лекарственного средства, содержащая геополимерное связующее
NZ603579A (en) 2009-06-24 2014-02-28 Egalet Ltd Controlled release formulations
US20130209560A1 (en) * 2010-02-24 2013-08-15 Cima Labs Inc. Abuse-resistant formulations
JP5968300B2 (ja) 2010-03-24 2016-08-10 ジャズ、ファーマシューティカルズ、インコーポレイテッドＪａｚｚ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． 高用量、水溶性及び吸湿性薬剤基質用の制御放出性剤形
US9877925B2 (en) 2010-05-14 2018-01-30 Ethypharm Alcohol-resistant oral pharmaceutical form
US20130059010A1 (en) * 2010-05-14 2013-03-07 Ethypharm Alcohol-resistant oral pharmaceutical form
FR2960775A1 (fr) * 2010-06-07 2011-12-09 Ethypharm Sa Microgranules resistants au detournement
CA2809927C (fr) 2010-09-07 2019-08-20 Orexo Ab Dispositif d'administration de medicament transdermique
CA2877183A1 (fr) 2012-07-06 2014-01-09 Egalet Ltd. Compositions pharmaceutiques de dissuasion d'abus a liberation controlee
HUE051406T2 (hu) 2012-11-14 2021-03-01 Grace W R & Co Biológiailag aktív anyagot és rendezetlen szervetlen oxidot tartalmazó kompozíciók
CN103330702B (zh) * 2013-07-02 2016-03-02 江苏长泰药业有限公司 含有拟交感神经胺盐和诱导凝胶体系的医药组合物
US10195153B2 (en) 2013-08-12 2019-02-05 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
EP3169315B1 (fr) 2014-07-17 2020-06-24 Pharmaceutical Manufacturing Research Services, Inc. Forme posologique remplie de liquide anti-abus à libération immédiate
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions
US20160106737A1 (en) 2014-10-20 2016-04-21 Pharmaceutical Manufacturing Research Services, Inc. Extended Release Abuse Deterrent Liquid Fill Dosage Form
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
JP6784596B2 (ja) * 2015-06-30 2020-11-11 第一三共株式会社 乱用防止機能を備えた医薬組成物
AU2017241266B2 (en) * 2016-03-31 2022-02-10 SpecGx LLC Extended release, abuse deterrent dosage forms
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
EP3473246A1 (fr) 2017-10-19 2019-04-24 Capsugel Belgium NV Formulations anti-abus à libération immédiate
KR20210094513A (ko) 2018-11-19 2021-07-29 재즈 파마슈티칼즈 아일랜드 리미티드 알코올-내성 약물 제형
JP2022522270A (ja) 2019-03-01 2022-04-15 フラメル アイルランド リミテッド 食事摂取状態における改善された薬物動態を有するガンマ－ヒドロキシ酪酸塩組成物
CA3138100A1 (fr) 2019-04-17 2020-10-22 Compass Pathfinder Limited Traitement de la depression et de divers autres troubles au moyen de psilocybine
CN110727226A (zh) * 2019-10-25 2020-01-24 河南大学 防止信息超载与作息紊乱的强弱电强制启闭系统
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6022562A (en) * 1994-10-18 2000-02-08 Flamel Technologies Medicinal and/or nutritional microcapsules for oral administration
US6309668B1 (en) * 1994-02-01 2001-10-30 Aventis Pharma Limited Abuse resistant tablets
FR2837100A1 (fr) * 2002-03-18 2003-09-19 Flamel Tech Sa Comprimes a bases de microcapsules a liberation modifiee
WO2003084518A2 (fr) * 2002-04-09 2003-10-16 Flamel Technologies Suspension orale de microcapsules de principes actifs
FR2842736A1 (fr) * 2002-07-26 2004-01-30 Flamel Tech Sa Formulation pharmaceutique orale sous forme d'une pluralite de microcapsules permettant la liberation prolongee de principe(s) actif(s) peu soluble(s)
WO2006056713A1 (fr) * 2004-11-24 2006-06-01 Flamel Technologies Forme pharmaceutique orale microparticulaire solide concue pour eviter le mesusage
WO2006056712A1 (fr) * 2004-11-23 2006-06-01 Flamel Technologies Forme medicamenteuse orale, solide et concue pour eviter le mesusage

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0477135A1 (fr) * 1990-09-07 1992-03-25 Warner-Lambert Company Microcapsules enduites sphéroidales mâchables et méthodes de leur préparation
CA2314896C (fr) * 1997-12-22 2005-09-13 Euro-Celtique, S.A. Procede prevenant l'abus des doses orales d'opioides
HUP0204163A2 (hu) * 2000-02-08 2003-04-28 Euro-Celtique S.A. Opioid agonistát és antagonistát tartalmazó szabályozott leadású készítmény és eljárás az előállítására
US7842307B2 (en) * 2001-08-06 2010-11-30 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
FR2830447B1 (fr) * 2001-10-09 2004-04-16 Flamel Tech Sa Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
IL164221A0 (en) * 2002-04-09 2005-12-18 Flamel Tech Sa Oral pharmaceutical formulation in the form of aqueous suspension of microcapsules for modified release of amoxicillim
CA2491572C (fr) * 2002-07-05 2010-03-23 Collegium Pharmaceutical, Inc. Compositions pharmaceutiques empechant la consommation abusive d'opioides et d'autres drogues
FR2842735B1 (fr) * 2002-07-26 2006-01-06 Flamel Tech Sa Microcapsules a liberation modifiee de principes actifs peu solubles pour l'administration per os

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309668B1 (en) * 1994-02-01 2001-10-30 Aventis Pharma Limited Abuse resistant tablets
US6022562A (en) * 1994-10-18 2000-02-08 Flamel Technologies Medicinal and/or nutritional microcapsules for oral administration
FR2837100A1 (fr) * 2002-03-18 2003-09-19 Flamel Tech Sa Comprimes a bases de microcapsules a liberation modifiee
WO2003084518A2 (fr) * 2002-04-09 2003-10-16 Flamel Technologies Suspension orale de microcapsules de principes actifs
FR2842736A1 (fr) * 2002-07-26 2004-01-30 Flamel Tech Sa Formulation pharmaceutique orale sous forme d'une pluralite de microcapsules permettant la liberation prolongee de principe(s) actif(s) peu soluble(s)
WO2006056712A1 (fr) * 2004-11-23 2006-06-01 Flamel Technologies Forme medicamenteuse orale, solide et concue pour eviter le mesusage
WO2006056713A1 (fr) * 2004-11-24 2006-06-01 Flamel Technologies Forme pharmaceutique orale microparticulaire solide concue pour eviter le mesusage

Also Published As

Publication number Publication date
JP2008529990A (ja) 2008-08-07
FR2881652A1 (fr) 2006-08-11
FR2881652B1 (fr) 2007-05-25
EP1845958A2 (fr) 2007-10-24
CN101151022A (zh) 2008-03-26
WO2006089843A2 (fr) 2006-08-31
US20090041838A1 (en) 2009-02-12
US20100266701A1 (en) 2010-10-21
CA2596965A1 (fr) 2006-08-31

Similar Documents

Publication Publication Date Title
WO2006089843A3 (fr) Forme medicamenteuse orale microparticulaire anti-mesusage
ATE553750T1 (de) Feste orale mikropartikelförmige darreichungsform zum schutz vor missbrauch
DE602005023203D1 (de) Zur verhinderung von missbrauch entworfene, feste arzneimittelform zur oralen verabreichung
WO2005041925A3 (fr) Compositions et formes posologiques permettant une absorption amelioree
EA200600696A1 (ru) Фармацевтические композиции для предотвращения передозировки или неправильного употребления лекарственных средств
WO2006125819A3 (fr) Forme medicamenteuse orale, microparticulaire, anti-mesusage
HK1139871A1 (en) Improvements in and relating to medicinal compositions
WO2004105694A3 (fr) Compositions pharmaceutiques et formes posologiques pour l'administration de medicaments hydrophobes
WO2004050020A3 (fr) Compositions pharmaceutiques opioïdes améliorées
WO2007126832A3 (fr) Compositions pharmaceutiques pour la prévention de la surdose ou de l'abus
WO2006050002A3 (fr) Compositions destinees a l'administration controlee de composes pharmaceutiquement actifs
WO2006022996A3 (fr) Forme posologique contenant des medicaments multiples
WO2007103293A3 (fr) Formulations à libération soutenue et résistant à l'éthanol
WO2005055921A3 (fr) Compositions pour le traitement de troubles auriculaires et procedes d'utilisation de ces compositions
WO2007112274A3 (fr) Formulations de médicaments anti-inflammatoires non stéroïdiens à faible dose et bêta-cyclodextrine
WO2006026592A3 (fr) Administration orale de medicaments faiblement absorbes, procedes et compositions associes
KR20090089867A (ko) 간독성 감소를 비롯한 부작용을 최소화한 아세트아미노펜 조성물
WO2004002445A3 (fr) Nouvelles formes posologiques flottantes
WO2008109385A3 (fr) Administration orale d'une calcitonine
MX2018000084A (es) Una composicion farmaceutica que comprende amlodipino, valsartan y rosuvastatina.
WO2012154587A3 (fr) Procédés de prévention d'interactions médicamenteuses toxiques dans des multithérapies comprenant des agents anti-erbb3
WO2005011579A3 (fr) Traitement de symptomes du sevrage
BRPI0520797B8 (pt) forma de dosagem farmacêutica comprimida em bicamadas
IL179177A (en) A pharmaceutical product including acyclovir and delivery compound, dosage unit, use of acyclovir in the preparation of the pharmaceutical product, use of the pharmaceutical product in the preparation of a drug and a method for the preparation of the pharmaceutical product
WO2008079343A3 (fr) Comprimés à désintégration par voie orale contenant une dose élevée de principes actifs: composition utilisée et méthodes de fabrication

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2596965

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007553626

Country of ref document: JP

Ref document number: 6160/DELNP/2007

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006708128

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200680009975.4

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2006708128

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11883935

Country of ref document: US